Topical ropivacaineAlternative Names: Ropivacaine DuraPeel
Latest Information Update: 30 Mar 2016
At a glance
- Originator ZARS Pharma
- Developer Nuvo Pharmaceuticals
- Class Amides; Local anaesthetics; Small molecules
- Mechanism of Action Potassium channel antagonists; Sodium channel antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase II Neuropathic pain
Most Recent Events
- 15 Mar 2016 Biomarkers information updated